Related Experiment Video
Updated: Mar 10, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
[Immunity and cancer associated thrombosis]
Andrzej Majdan1, Aleksandra Majdan2, Patrycja Ziober-Malinowska3
1Katedra i Zakład Onkologii, Uniwersytet Medyczny, Lublin,
Abstract:
In cancer patients, thrombosis is commonly found complication. There are many established risk factors which may be responsible for thrombosis in this group of patients. Especially the factors connected with treatment and the cancer itself, seem to be significant in the pathogenesis of thromboembolism. On the other hand, the reactions between cancer, hemostasis and immunological system seem to be important in initiation of the thrombotic process. In this review, on the basis of current literature, we have analyzed the relationship between neoplasmatic thrombosis and immunological disorders. The lack of balance between immunological system and haemostasis in neoplasms is the key issue to solve, in order to correct the long term cancer survival.
Related Concept Videos
Tumor Immunotherapy
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Tumor Microenvironment
Cell-mediated Immune Responses
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

